Should You Buy ENDRA Life Sciences Inc (NDRA) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/30
NDRA is not a good buy right now. The technical setup remains bearish (downtrend with weakening momentum), proprietary signals show no buy trigger, and the short-term pattern stats skew negative (expected drift lower over day/week/month). With an impatient profile and no supportive catalysts in the provided data, the risk/reward favors avoiding or selling rather than buying at ~$3.80 pre-market.
Technical Analysis
Trend/Momentum: Bearish. Moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), confirming a broader downtrend. MACD histogram is negative (-0.00801) and expanding to the downside, suggesting bearish momentum is strengthening. RSI(6) at 33.7 is near oversold but still classified as neutral here—this can produce short bounces, but not a confirmed reversal.
Levels: Current pre-market price (~3.80) is below S2 (3.919) and well below pivot (4.43), indicating the stock is trading in a weak zone. First meaningful resistance is S2/4.11 area (S1 4.114), then pivot 4.43.
Stat/Pattern outlook: Similar-pattern analysis implies a 60% chance of further declines: -0.56% next day, -0.97% next week, -2.62% next month.
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): no signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.